Skip to main content

Peer Review reports

From: Superior efficacy of rituximab-based chemoimmunotherapy as an initial therapy in newly diagnosed patients with B cell indolent lymphomas: long-term results from a single center in China

Original Submission
10 Feb 2015 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
Resubmission - Version 3
Submitted Manuscript version 3
Resubmission - Version 4
Submitted Manuscript version 4
Resubmission - Version 5
Submitted Manuscript version 5
Resubmission - Version 6
Submitted Manuscript version 6
Reviewed Reviewer Report
Reviewed Reviewer Report
Reviewed Reviewer Report
Resubmission - Version 7
Submitted Manuscript version 7
Reviewed Reviewer Report
Reviewed Reviewer Report
Resubmission - Version 8
Submitted Manuscript version 8
Publishing
7 Jul 2015 Editorially accepted
29 Jul 2015 Article published 10.1186/s12885-015-1534-0

You can find further information about peer review here.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us